Related Experiment Video
Updated: Aug 11, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Antimicrobial therapy of pneumonia in infants and children
1Maxwell Finland Laboratory for Infectious Disease, Boston City Hospital, MA 02118, USA.
Insights
Optimal management of childhood community-acquired pneumonia requires considering pathogen frequency, antibiotic resistance, and clinical presentation. New antibiotic options and outpatient parenteral therapy improve treatment outcomes for pediatric pneumonia.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Community-acquired pneumonia (CAP) in children necessitates careful management considering diverse etiologies.
- Identifying the specific pathogen is challenging, influencing initial antibiotic selection based on age, local resistance, and clinical data.
- Streptococcus pneumoniae and Haemophilus influenzae are common bacterial causes, with increasing concerns regarding multidrug-resistant strains and evolving H. influenzae epidemiology.
Purpose of the Study:
- To guide clinicians in selecting optimal management strategies for pediatric community-acquired pneumonia.
- To review current therapeutic options considering evolving pathogen resistance and new antimicrobial agents.
- To highlight advancements in treatment that may reduce the need for hospital admission.
Main Methods:
- Review of etiological factors and common pathogens in pediatric CAP.
- Analysis of antibiotic resistance patterns and their impact on treatment choices.
- Evaluation of current and emerging pharmacotherapies, including macrolides and extended-spectrum cephalosporins.
- Assessment of the role of outpatient parenteral antibiotic therapy (OPAT).
Main Results:
- Amoxicillin or oral cephalosporins are recommended for mild to moderate CAP.
- Extended-spectrum cephalosporins or vancomycin are options for severe or penicillin-unresponsive pneumococcal pneumonia.
- Newer macrolides (azithromycin, clarithromycin) offer effective treatment for Mycoplasma pneumonia in older children.
- Ceftriaxone enables once-daily intramuscular outpatient therapy for serious CAP, potentially avoiding hospitalization.
Conclusions:
- Optimal CAP management in children integrates pathogen data, resistance patterns, and clinical assessment.
- Advances in antibiotics and outpatient parenteral therapy have expanded treatment options and improved outcomes.
- Outpatient parenteral therapy for serious CAP cases can reduce hospital admissions, enhancing patient care and resource utilization.
Abstract:
To provide optimal management for the child with community-acquired pneumonia, the clinician must take multiple factors into consideration. The etiology of pneumonia is difficult to determine and initial choice of therapy is based on the frequency of pathogens in various age groups, local antibiotic resistance patterns of the organisms, clinical presentation, and epidemiological data. Streptococcus pneumoniae and Haemophilus influenzae remain the most common bacterial pathogens outside the newborn period. Increasing numbers of multidrug-resistant strains of S pneumoniae in the United States and Europe, the decline in H influenzae type b because of current vaccination strategies, and increasing recognition of nontypeable H influenzae as etiologic agents of pneumonia have prompted reconsideration of the drug of choice. Amoxicillin and its derivatives or oral cephalosporins are the drugs of choice for initial therapy for mild to moderate disease. For severe disease or if beta-lactamase producing organisms are a concern, extended spectrum cephalosporins are indicated. Pneumococcal pneumonia unresponsive to penicillin therapy may warrant the use of extended spectrum cephalosporins or vancomycin. For older children in whom mycoplasma is a significant cause of pneumonia, the new macrolides have provided additional options for the clinician. Azithromycin and clarithromycin are efficacious, well tolerated, and require less frequent dosing intervals. The introduction of ceftriaxone, a third-generation cephalosporin with a broad spectrum of activity and prolonged half-life, allows once-a-day intramuscular therapy that can be administered on an outpatient basis. With the availability of parenteral outpatient therapy, hospital admission is no longer required for the treatment of most cases of serious community-acquired pneumonia.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
03:22Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
Published on: March 1, 2024
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:14Atypical Pneumonia
01:29Pneumonia I: Introduction